- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Archer Files Patent Application for Graphene Biosensor Technology
Archer Materials has filed a patent application to protect and commercialise its graphene biosensor technology intellectual property.
Archer Materials (ASX:AXE) announced that it has filed a patent application under the Patent Cooperation Treaty to protect and commercialise its graphene biosensor technology intellectual property. The company is aiming to use graphene materials to solve biosensing challenges.
Highlights of the announcement are as follows:
- Archer files patent application under the Patent Cooperation Treaty (“International Patent Application”).
- International Patent Application filed to protect and commercialise graphene biosensor technology intellectual property (“IP”).
- Archer maintains 100% ownership of the International Patent Application and related IP.
- The global biosensor market is part of the emerging Medtech industry where patents are important licensable assets and sources of revenue1,2,3
Dr. Mohammad Choucair, CEO of Archer, commented:
One of Archer’s key execution priorities to deliver value to our shareholders is to prosecute patents related to the development of graphene-based biosensor technology.
Filing an international patent application represents the first step in the commercialisation of the Company’s graphene biosensor technology. Importantly, Archer independently generated the IP, and maintains 100% ownership of this new [Company] asset, that has the potential to positively disrupt the emerging Medtech industry.
Click here to read the full Archer Materials (ASX:AXE) press release.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.